This inventor holds 1 USPTO granted patent. Top assignee: Medimmune Limited. Active years: 2026.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2026
Title: Michelle Morrow: Innovator in Targeted Binding Agents
Introduction
Michelle Morrow is a notable inventor based in Cambridge, MA (US). He has made significant contributions to the field of biotechnology, particularly in the development of targeted binding agents. His innovative work has led to the filing of a patent that showcases his expertise and dedication to advancing medical science.
Latest Patents
Michelle Morrow holds a patent for "Targeted Binding Agents Against B7-H1." This patent represents a crucial advancement in the understanding and treatment of various diseases, particularly in the realm of immunotherapy. His work in this area is expected to have a lasting impact on therapeutic strategies.
Career Highlights
Morrow is currently employed at MedImmune Limited, a leading biotechnology company. His role at MedImmune has allowed him to collaborate with other experts in the field and contribute to groundbreaking research. His career is marked by a commitment to innovation and excellence in biotechnology.
Collaborations
One of his notable collaborators is Christophe Queva. Together, they have worked on various projects that aim to enhance the efficacy of targeted therapies. Their partnership exemplifies the collaborative spirit that drives innovation in the scientific community.
Conclusion
Michelle Morrow is a distinguished inventor whose work in targeted binding agents is paving the way for new therapeutic approaches. His contributions to MedImmune Limited and the field of biotechnology highlight the importance of innovation in improving healthcare outcomes.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile